Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis2018-01-17T17:02:43-05:00
Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis2018-01-17T17:02:43-05:00
